Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851856)
Watch
English
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
22805292
retrieved
13 November 2016
title
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
(English)
1 reference
stated in
PubMed
PubMed ID
22805292
retrieved
13 November 2016
main subject
phase I clinical trial
0 references
patient
0 references
author
Razelle Kurzrock
series ordinal
21
object named as
Razelle Kurzrock
0 references
Keith Flaherty
series ordinal
18
object named as
Keith Flaherty
0 references
Jeffrey R Infante
series ordinal
3
object named as
Jeffrey R Infante
0 references
Vijay G R Peddareddigari
series ordinal
11
object named as
Vijay G R Peddareddigari
0 references
Leslie A Fecher
series ordinal
22
object named as
Leslie A Fecher
0 references
Douglas J DeMarini
series ordinal
6
object named as
Douglas J DeMarini
0 references
Howard A Burris
series ordinal
14
object named as
Howard A Burris
0 references
Ngocdiep T Le
series ordinal
13
object named as
Ngocdiep T Le
0 references
author name string
Gerald S Falchook
series ordinal
1
0 references
Karl D Lewis
series ordinal
2
0 references
Michael S Gordon
series ordinal
4
0 references
Nicholas J Vogelzang
series ordinal
5
0 references
Peng Sun
series ordinal
7
0 references
Christopher Moy
series ordinal
8
0 references
Stephen A Szabo
series ordinal
9
0 references
Lori T Roadcap
series ordinal
10
0 references
Peter F Lebowitz
series ordinal
12
0 references
Wells A Messersmith
series ordinal
15
0 references
Peter J O'Dwyer
series ordinal
16
0 references
Kevin B Kim
series ordinal
17
0 references
Johanna C Bendell
series ordinal
19
0 references
Rene Gonzalez
series ordinal
20
0 references
publication date
August 2012
0 references
published in
Lancet Oncology Commission
0 references
volume
13
0 references
issue
8
0 references
page(s)
782-9
0 references
cites work
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Mutations in GNA11 in uveal melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
MEK1 mutations confer resistance to MEK and B-RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
Mutations of the BRAF gene in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
20 March 2017
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
7 April 2017
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Mutation and copy number detection in human cancers using a custom genotyping assay
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Resistance to MEK inhibitors: should we co-target upstream?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Management of cutaneous melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
29 September 2017
Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
2 June 2018
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109286
retrieved
27 November 2018
N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22805292
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970269-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970269-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(12)70269-3
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2427625
OpenCitations bibliographic resource ID
2427625
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2427625
PMCID
4109286
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2427625
PubMed ID
22805292
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2427625
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
